Pharma: Clinic Roundup

• CSL Behring, of King of Prussia, Pa., reported data from a single-arm, open-label study showing that Privagen (immune globulin intravenous [human], 10 percent liquid), an intravenous immunoglobulin (IVIG), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy.